Division of Clinical Methods and Public Health, Academic Medical Center, University of Amsterdam, Meibergdreef 15, Amsterdam, The Netherlands.
J Clin Epidemiol. 2010 Dec;63(12):1342-50. doi: 10.1016/j.jclinepi.2010.01.018. Epub 2010 Jun 16.
To identify prognostic indicators of the publication rate of clinical studies, available to research ethics committees (RECs) during review.
Retrospective survival study of a random sample of 100 studies, approved by a Dutch academic REC, with follow-up information by questionnaire and bibliographic searches. Multivariate Cox regression analysis of the association between publication rate and seven factors available during review: six study characteristics and the number of letters sent by the committee during review representing the length of the review process.
Two factors were associated with publication rate: studies with possible therapeutic benefit to participants were less likely to be published than nontherapeutic studies (adjusted hazard ratio [AHR]: 0.16; 95% confidence interval [CI]: 0.03-0.54); with every letter sent, publication was less likely (AHR: 0.46 per letter; 95% CI: 0.17-0.98). Possibly, studies with more-than-minimal burdens to participants were more likely to be published than studies with minimal burdens (AHR: 3.90, 95% CI: 1.03-16.64).
We identified two prognostic indicators of publication rate. After suitable replication, RECs might explore using prognostic indicators, such as these, to target study protocols at high risk for nonpublication. Discussing the risk of nonpublication with investigators could help prevent nonpublication.
确定研究伦理委员会(REC)审查时可获得的临床研究发表率的预后指标。
对荷兰学术 REC 批准的 100 项研究的随机样本进行回顾性生存研究,通过问卷调查和文献检索获得随访信息。采用多变量 Cox 回归分析发表率与审查期间可用的七个因素之间的关联:六个研究特征和委员会在审查期间发送的信件数量,代表审查过程的长度。
有两个因素与发表率相关:对参与者有潜在治疗益处的研究比非治疗性研究更不可能发表(调整后的危险比 [AHR]:0.16;95%置信区间 [CI]:0.03-0.54);每封信的发表可能性都降低(AHR:每封信 0.46;95%CI:0.17-0.98)。可能是,对参与者造成的负担大于最小的研究比负担最小的研究更有可能发表(AHR:3.90,95%CI:1.03-16.64)。
我们确定了两个发表率的预后指标。在适当的复制后,REC 可以探索使用这些预后指标,针对发表风险高的研究方案。与研究人员讨论不发表的风险可能有助于防止不发表。